NEW YORK, Nov. 23, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Opus Bank (NASDAQ:OPB) securities between July 28, 2014 and October 17, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/opus-bank. There is no cost or obligation to you.
According to the complaint, during the Class Period, Opus Bank made false and/or misleading statements and/or failed to disclose that: (a) some of the Company’s loans were of low quality; (b) Opus Bank was over-representing the quality of the loans to the public; (c) the Company failed to properly account for the loans in violation of the Generally Accepted Accounting Principles; (d) the Company would be forced to recognize large charge-offs associated with the loans; (e) Opus Bank lacked adequate internal controls over accounting and financial reporting; and (f) as a result of the above, the Company’s statements about its business, operations and prospects were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Opus Bank you have until December 27, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/opus-bank.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]


Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 



